The pathogenesis of thromboembolic disease in covid-19 patients: Could be a catastrophic antiphospholipid syndrome?

Yang, 2020, Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study, Lancet Respir. Med., 10.1016/S2213-2600(20)30079-5

Zhou, 2020, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, 395, 1054, 10.1016/S0140-6736(20)30566-3

Taylor, 2001, Towards a definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation, J. Thromb. Haemost., 86, 1327, 10.1055/s-0037-1616068

Rodriguez-Pinto, 2015, Catastrophic APS in the context of other thrombotic microangiopathies, Curr. Rheumatol. Rep., 10.1007/s11926-014-0482-z

Rodriguez-Pinto, 2016, Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the International CAPS Registry, Autoimmun. Rev., 15, 1120, 10.1016/j.autrev.2016.09.010

Klok, 2020, Incidence of thrombotic complications in critically ill ICU patients with COVID-19, Thromb. Res.

Tang, 2020, Anticoagulant treatment is associated with decreased mortality in coronavirus disease 2019 patients with coagulopathy, J Thromb Haemost

Carsana, 2020, Pulmonary post-mortem findings in a large series of COVID-19 cases from Northern Italy, MedXrive

Zhang, 2020, Coagulopathy and antiphospholipid antibodies in patients with COVID-19, N. Engl. J. Med., 10.1056/NEJMc2007575

Litvinova, 2018, Prevalence and significance of non-conventional antiphospholipid antibodies in patients with clinical APS criteria, Front. Immunol., 10.3389/fimmu.2018.02971